Indication-Based Pricing Hurdle A Block For Roche's Ocrevus In UK
Executive Summary
The UK's National Institute for Health and Care Excellence rejected Roche's ocrelizumab for provision to adults with primary progressive multiple sclerosis due to cost grounds and efficacy uncertainties - but observers expect a compromise to be eventually struck.